LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial
B.C. Cho, Enriqueta Felip, Alexander I. Spira et al. · Annals of Oncology · 2023
Cited by 83 works. doi:10.1016/j.annonc.2023.10.062 Open-access PDF
Authors
- B.C. Cho
- Enriqueta Felip
- Alexander I. Spira
- Nicolas Girard
- Jin Sun Lee
- Soo Hoon Lee
- Y.V. Ostapenko
- Pongwut Danchaivijitr
- B. Liu
- Adlinda Alip
- Ernesto Pablo Korbenfeld
- Josiane Mourão Dias
- Tao Sun
- Joshua Michael Bauml
- S. Martin Shreeve
- Seema Niphadkar Sethi
- Roland Elmar Knoblauch
- Hidetoshi Hayashi
- Shun Lü